Press release
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
– Additional Phase 3 PURPOSE Data Reinforce the Safety Profile of Twice-Yearly Yeztugo® as an Effective HIV Prevention Option Across Diverse Populations – –
About this update from Gilead Sciences, Inc.
[{"type":"text","content":"\n– Additional Phase 3 PURPOSE Data Reinforce the Safety Profile of Twice-Yearly Yeztugo® as an Effective HIV Prevention Option Across Diverse Populations –\n\n\n– New Data Show Higher Treatment Satisfaction After Switching from IM CAB+RPV to Biktarvy® –\n\n\n– New Research Reaffirms Veklury® in High-Risk COVID-19 Populations and Obeldesivir in Emerging Pathogens –\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead’s leadership in advancing antiviral science and its ongoing efforts to bring forward innovative solutions for people and communities most affected by infectious diseases.\n\n\n“At IDWeek 2025, we look forward to presenting new data that reflect our ongoing commitment to developing transformational medicines for hepatitis, as well as HIV prevention and treatment, and to expanding that goal to respiratory and other viruses causing serious disease,” said Jared Baeten, MD, PhD, Senior Vice President, Virology Therapeutic Area Head, Gilead Sciences. “These studies highlight the strength and depth of our antiviral portfolio and expanding pipeline, and our focus on person-centered innovation to help address the diverse and evolving needs of people and communities affected by serious viral diseases in the U.S. and around the world.”\n\n\nHIV Prevention Research\n\n\nNew pivotal PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) data provided further insight into the safety of twice-yearly Yeztugo® (lenacapavir – or LEN) for pre-exposure prophylaxis (PrEP). Sub-analyses among PURPOSE 1 trial participants using progestin-type long-acting (LA) hormonal contraceptives (implants or injections) and PURPOSE 2 trial participants using gender-affirming hormone therapy (GAHT) showed no clinically significant drug-drug interactions between Yeztugo and these commonly-used products.\n\n\nFindings from PURPOSE 2 also assessed Yeztugo adherence and safety among individuals who reported using stimulants and opioids. These data – from the most gender-diverse HIV prevention trial to date – underscore Yeztugo’s potential a...